RPG Life Sciences shareholders approved a final dividend of ₹24 per equity share for the financial year ended March 31, 2026, during its 19th Annual General Meeting (AGM) held on July 23, 2026. The resolution passed with overwhelming support, reflecting strong shareholder confidence in the company’s capital return strategy. The meeting also addressed key governance matters, including the reappointment of directors and the ratification of cost auditor remuneration.

The AGM was conducted via video conferencing in compliance with Ministry of Corporate Affairs (MCA) and SEBI circulars. Harsh V. Goenka, Chairman of the company, presided over the proceedings. The quorum was established with 20 promoters and 20 public shareholders attending virtually. Statutory auditors SRBC & Co. LLP and secretarial auditors Parikh Parekh & Associates were represented at the meeting. Mitesh Dhaliwala of Parikh Parekh & Associates served as the scrutinizer for the voting process.

All six resolutions placed before the members were passed with the requisite majority. The most significant outcome was the declaration of a 300% dividend on equity shares with a face value of ₹8 each. This ordinary resolution received 100% support from votes polled, with only six votes cast against it out of more than 13 million total votes.

Key Resolutions Passed

Shareholders voted on several critical items concerning board composition and statutory appointments. The voting results, scrutinized by Parikh Parekh & Associates, are detailed below:

Harsh V. Goenka and Manoj Maheshwari were reappointed as Non-Executive Non-Independent Directors upon retirement by rotation under Section 152(6) of the Companies Act, 2013. Both resolutions secured nearly unanimous support, with approximately 87,754 votes cast against each appointment out of 13.1 million votes polled.

Dr. Pratit Samdani was appointed as an Independent Director for a five-year term commencing April 29, 2026, and ending April 28, 2031. This special resolution passed with 99.99% approval, indicating minimal dissent among the shareholder base.

Governance and Compliance

The company ratified the remuneration payable to Kirit Mehta & Co., its cost auditors, for the financial year ending March 31, 2027. This ordinary resolution was approved with 100% of the votes polled in favor.

The voting process utilized the National Securities Depository Limited (NSDL) e-voting platform. Remote e-voting commenced on July 20, 2026, and concluded on July 22, 2026. Shareholders present at the virtual AGM who had not voted remotely were given an additional 15 minutes to cast their ballots. The cut-off date for voting eligibility was July 16, 2026, with a total of 24,393 shareholders on record. The meeting concluded at 3:38 p.m., following the closure of the e-voting window.

RPG Life Sciences has partnered with Archerchem Healthcare to launch Naprosyn ES in India, a combination medication designed to provide effective anti-inflammatory solutions along with gastro-protection. This strategic collaboration marks the first introduction of a Naproxen and Esomeprazole combination in the Indian market, addressing a significant unmet need for patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy. The partnership strengthens the existing business relationship between the two entities, with RPG Life Sciences serving as the exclusive marketing and distribution partner while Archerchem acts as the exclusive supplier.

Partnership Details

Under the agreement, RPG Life Sciences will leverage the strong legacy and brand recall of the Naprosyn brand to drive distribution across the country. The dual-action formulation is designed to provide efficient pain management through Naproxen, a well-established NSAID, while Esomeprazole works to safeguard the gastrointestinal lining. This differentiated formulation is expected to improve patient compliance and enable safer long-term pain management, particularly among elderly and gastro-sensitive populations.

Strategic Impact

Ashok Nair, Managing Director of RPG Life Sciences, stated that the launch exemplifies the company's R&D-driven approach to differentiated products and the trust placed by doctors and patients in the Naprosyn brand. Anil Dhedia, Chairman & Managing Director of Archerchem Healthcare, highlighted the partnership as a demonstration of Archerchem's strength in developing complex differential formulations. The launch aligns with RPG Life Sciences' continued focus on building a differentiated portfolio in chronic therapy segments, utilizing its robust reach to a wide spectrum of doctors and pan-India distribution network.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE105J01010/5615a4bb-1d1c-497d-937c-dc856287e98c.pdf